Passive and oxymetazoline-enhanced delivery with a lens device: Pharmacokinetics and efficacy studies with rabbits

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 4, 2008, Pages 385-391

  Miller, David J ^a   Li, S Kevin ^a,c   Tuitupou, Anthony L ^a   Kochambilli, Rajan P ^a,b   Papangkorn, Kongnara ^a,b   Mix Jr , Donald C ^a   Higuchi, William I ^a,b   Higuchi, John W ^a  

^a Aciont Inc   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; OXYMETAZOLINE; SILICONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; MEAN RESIDENCE TIME; MONOTHERAPY; NONHUMAN; RABBIT; SAFETY; SCLERA; SCORING SYSTEM; UVEITIS;

ANIMALS; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; LENS, CRYSTALLINE; MALE; OXYMETAZOLINE; RABBITS; UVEITIS;

EID: 48349100977     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0116     Document Type: Article

References (42)

1. Geroski, D.H., and Edelhauser, H.F. Transscleral drug delivery for posterior segment disease. Adv. Drug Deliv. Rev. 52:37-48, 2001.
2. Lee, V.H., and Robinson, J.R. Topical ocular drug delivery: Recent developments and future challenges. J. Ocul. Pharmacol. Ther. 2:67-108, 1986.
3. Davies, N.M. Biopharmaceutical considerations in topical ocular drug delivery. Clin. Exp. Pharmacol. Physiol. 27: 558-562, 2000.
4. Hwang, D.G., Stern, W.H., Hwang, P.H., et al. Collagen shield enhancement of topical dexamethasone penetration. Arch. Ophthalmol. 107:1375-1380, 1989.
5. Loftsson, T., and Stefansson, E. Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye. Acta. Ophthalmol. Scand. 80:144-150, 2002.
6. Mainardes, R.M., Urban, M.C., Cinto, P.O., et al. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targ. 6:363-371, 2005.
7. Bartlett, J.D., Jaanus, S.D., and Blaho, K.E. Clinical Ocular Pharmacology. Boston: Butterworth-Heinemann, 2001.
8. Lee, T.W., and Robinson, J.R. Drug delivery to the posterior segment of the eye II: Development and validation of a simple pharmacokinetic model for subconjunctival injection. J. Ocul. Pharmacol. Ther. 20:43-53, 2004.
9. Robinson, M.R., Lee, S.S., Kim, H., et al. A rabbit model for assessing the ocular barriers to the trans-scleral delivery of triamcinolone acetonide. Exp. Eye Res. 82:479-487, 2006.
10. Urtti, A., and Salminen, L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37:435-456, 1993.
11. Ogura, Y. Preface: Drug delivery to the posterior segment of the eye. Adv. Drug Deliv. Rev. 52:1-3, 2001.
12. Lam, T.T., Edward, D.P., Zhu, X.A., et al. Trans-scleral ion-tophoresis of dexamethasone. Arch. Ophthalmol. 107:1368-1371, 1989.
13. Greenwood, J. The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): A review. Curr. Eye Res. 11(Suppl):25-32, 1992.
14. Kulkarni, P.S. Steroidal and nonsteroidal drugs in endotoxin-induced uveitis. J. Ocul. Pharmacol. Ther. 10:329-334, 1994.
15. Weijtens, O., van der Sluijs, F.A., Schoemaker, R.C., et al. Peribulbar corticosteroid injection: Vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am. J. Ophthalmol. 123:358-363, 1997.
16. Kyyronen, K., and Urtti, A. Improved ocular: Systemic absorption ratio of timolol by viscous vehicle and phenylephrine. Invest. Ophthalmol. Vis. Sci. 31:1827-1833, 1990.
17. Stein, J., and Coogan, M. New treatment for eye disease reduces need for strong drugs. NEI Press Release, 1997.
18. Goodman, L.S., Gilman, A., Hardman, J.G., et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, Health Professions Division, 1996.
19. Jaffe, G.J., McCallum, R.M., Branchaud, B., et al. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112:1192-1198, 2005.
20. Kodama, M., Numaga, J., Yoshida, A., et al. Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Graefe's Arch. Clin. Exp. Ophthalmol. 241:927-933, 2003.
21. Kulkarni, P.S., and Paterson, C.A. Diclofenac and prednisolone inhibit endotoxin-induced uveitis in rabbits. Exp. Eye Res. 61:767-768, 1995.
22. Bodker, F.S., Ticho, B.H., Feist, R.M., et al. Intraocular dexamethasone penetration via subconjunctival or retrobulbar injections in rabbits. Ophthalmic Surg. 24:453-457, 1993.
23. Cheng, C.K., Berger, A.S., Pearson, P.A., et al. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest. Ophthalmol. Vis. Sci. 36:442-453, 1995.
24. Fialho, S.L., and da Silva-Cunha, A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin. Exp. Ophthalmol. 32:626-632, 2004.
25. Kozak, I., Kayikcioglu, O.R., Cheng, L., et al. The effect of recombinant human hyaluronidase on dexamethasone penetration into the posterior segment of the eye after sub-Tenon's injection. J. Ocul. Pharmacol. Ther. 22:362-369, 2006.
26. Loftsson, T., Hreinsdottir, D., and Stefansson, E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: Aqueous dexamethasone eye drops. J. Pharm. Pharmacol. Ther. 59:629-635, 2007.
27. Weijtens, O., Feron, E.J., Schoemaker, R.C., et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. 128:192-197, 1999.
28. Weijtens, O., Schoemaker, R.C., Romijn, F.P., et al. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 109:1887-1891, 2002.
29. Lee, T.W., and Robinson, J.R. Drug delivery to the posterior segment of the eye: some insights on the penetration pathways after subconjunctival injection. J. Ocul. Pharmacol. Ther. 17:565-572, 2001.
30. Li, S.K., Molokhia, S.A., and Jeong, E.K. Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging. Pharm. Res. 21:2175-2184, 2004.
31. Duzman, E., Anderson, J., Vita, J.B., et al. Topically applied oxymetazoline. Ocular vasoconstrictive activity, pharmacokinetics, and metabolism. Arch. Ophthalmol. 101:1122-1126, 1983.
32. Gobbels, M.J., Achten, C., and Spitznas, M. Effect of topically applied oxymetazoline on tear volume and tear flow in humans. Graefe's Arch. Clin. Exp. Ophthalmol. 229:147-149, 1991.
33. Wang, R.F., Lee, P.Y., Taniguchi, T., et al. Effect of oxymetazoline on aqueous humor dynamics and ocular blood flow in monkeys and rabbits. Arch. Ophthalmol. 111:535-538, 1993.
34. Chu, T.C., Ogidigben, M.J., and Potter, D.E. Oxymetazoline: Potential mechanisms of inhibitory effects on aqueous humor dynamics. Pharmacology 53:259-270, 1996.
35. Rudnick, D.E., Noonan, J.S., Geroski, D.H., et al. The effect of intraocular pressure on human and rabbit scleral permeability. Invest. Ophthalmol. Vis. Sci. 40:3054-3058, 1999.
36. Chou, P.I., Lu, D.W., and Chen, J.T. Adrenergic supersensitivity of rabbit choroidal blood vessels after sympathetic denervation. Curr. Eye Res. 23:352-356, 2001.
37. Weigert, G., Resch, H., Garhofer, G., et al. Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting. Invest. Ophthalmol. Vis. Sci. 48:4220-4225, 2007.
38. Fox, S.L., Samson, C.R., and Danzig, M.R. Oxymetazoline in the treatment of allergic and noninfectious conjunctivitis. J. Int. Med. Res. 7:528-530, 1979.
39. Xuan, B., and Chiou, G.C. Efficacy of oxymetazoline eye drops in noninfectious conjunctivitis, the most common cause of acute red eyes. J. Ocul. Pharmacol. Ther. 13:363-367, 1997.
40. Duzman, E., Warman, A., and Warman, R. Efficacy and safety of topical oxymetazoline in treating allergic and environmental conjunctivitis. Ann. Ophthalmol. 18:28-31, 1986.
41. Samson, C.R., Danzig, M.R., Sasovetz, D., et al. Safety and toleration of oxymetazoline ophthalmic solution. Pharmatherapeutica 2:347-352, 1980.
42. Polska, E., Simader, C., Weigert, G., et al. Regulation of choroidal blood flow during combined changes in intraocular pressure and arterial blood pressure. Invest. Ophthalmol. Vis. Sci. 48:3768-3774, 2007.